AMENDMENTS TO THE CLAIMS

1. (currently amended) A compound having the structure



wherein

R^1 is an alkyl group comprising 2-6 carbon atoms,

R^2 is selected from the group consisting of hydrogen and protecting groups,

R^3 is an optionally substituted alkyl group comprising 1-4 carbon atoms, and

Z is L-X-Q wherein L ~~comprises 1-15 carbon atoms, one of which is directly linked to the phenyl ring, and 0-6 heteroatoms~~ is $(CH_2)_3$, X is ~~selected from the group consisting of O,~~ CO, ~~NR4, S, C(=NH)O, NH(CO), NH(CO)NH, NH(CS), NH(CS)NH, O(CO)NH, and NH(C=NH), wherein R4 is selected from the group consisting of hydrogen and alkyl groups comprising 1-4 carbon atoms,~~ and Q is selected from the group consisting of macromolecular carriers and labels.

2. (original) The compound of claim 1 wherein the macromolecular carrier is selected from the group consisting of proteins, polypeptides, and polysaccharides.

3. (original) The compound of claim 1 wherein the macromolecular carrier is selected from the group consisting of keyhole limpet hemocyanin, bovine serum albumin, and bovine thyroglobulin.

4-9 (cancelled)

10. (original) Cell line NEAMP 48.2, ATCC designation PTA-5295, producing a monoclonal antibody binding preferentially to MDEA.

11. (original) A monoclonal antibody produced from cell line NEAMP 48.2, ATCC designation PTA-5295, the antibody binding preferentially to MDEA.

12. (cancelled)

13. (original) Cell line NEAMP 62.1, ATCC designation PTA-5294, producing a monoclonal antibody binding preferentially to MDEA.

14. (original) A monoclonal antibody produced from cell line NEAMP 62.1, ATCC designation PTA-5294, the antibody binding preferentially to MDEA.

15-21 (cancelled)

22. (currently amended) An antibody generated in response to a compound having the structure



wherein

R^1 is an alkyl group comprising 2-6 carbon atoms,

R^2 is selected from the group consisting of hydrogen and protecting groups,

R^3 is an optionally substituted alkyl group comprising 1-4 carbon atoms, and

Z is L-X-Q wherein L ~~comprises 1-15 carbon atoms, one of which is directly linked to the phenyl ring, and 0-6 heteroatoms~~ is $(CH_2)_3$, X is ~~selected from the group consisting of O,~~ CO, ~~NR4, S, C(=NH)O, NH(CO), NH(CO)NH, NH(CS), NH(CS)NH, O(CO)NH, and NH(C=NH), wherein R4 is selected from the group consisting of hydrogen and alkyl groups comprising 1-4 carbon atoms,~~ and Q is a macromolecular carrier selected from the group consisting of proteins, polypeptides, and polysaccharides.

23. (original) The antibody of claim 22 wherein the protein is selected from the group consisting of keyhole limpet hemocyanin, bovine serum albumin, and bovine thyroglobulin.

24. (cancelled)

25. (currently amended) The antibody of ~~claim 24~~ claim 22 wherein R^1 is ethyl and R^3 is methyl.

26-28 (cancelled)

29. (currently amended)



wherein

R^1 is an alkyl group comprising 2-6 carbon atoms,

R^2 is selected from the group consisting of hydrogen and protecting groups,

R^3 is an optionally substituted alkyl group comprising 1-4 carbon atoms, and

Z is L-X-Q wherein L ~~comprises 1-15 carbon atoms, one of which is directly linked to the phenyl ring, and 0-6 heteroatoms~~ is $(CH_2)_1$, X is ~~selected from the group consisting of O,~~ CO, ~~NR4, S, C(=NH)O, NH(CO), NH(CO)NH, NH(CS), NH(CS)NH, O(CO)NH, and NH(C=NH), wherein R4 is selected from the group consisting of hydrogen and alkyl groups comprising 1-4 carbon atoms,~~ and Q is a macromolecular carrier selected from the group consisting of proteins, polypeptides, and polysaccharides.

30. (cancelled)

31. (original) The method of claim 29 wherein R^1 is ethyl and R^3 is methyl.

32. (original) The method of claim 29 wherein Q is a protein selected from the group consisting of hemocyanins, globulins, and albumins.

33. (currently amended) A method for detecting an analyte in a sample, the analyte comprising an ecstasy drug or an ecstasy drug derivative, comprising:

contacting the sample with the antibody of ~~claim 16~~ claim 22 and a conjugate comprising an analyte analog and a detectable label whereby the analyte and the analyte analog compete for binding to the antibody, and

measuring the labeled conjugate bound to the antibody or measuring the unbound labeled conjugate as a measure of the analyte in the sample.

34-38 (cancelled)